Interpretation of the guideline on prevention and treatment for chronic hepatitis B (2010 version) -the goals and indications for chronic hepatitis B treatment

[3]Chen YC, Chu CM, Yeh CT, et al.Natural course following theonset of cirrhosis in patients with chronic hepatitis B:a long-termfollow-up study[J].Hepatol Int, 2007, 1 (1) :267-273.

[4]Liaw YF.Natural history of chronic hepatitis B virus infection andlong-term outcome under treatment[J].Liver Int, 2009, 29 (Sup-pl 1) :100-107.

[5]Yuen MF, Wong DK, Fung J, et al.HBsAg Seroclearance inchronic hepatitis B in Asian patients:replicative level and risk ofhepatocellular carcinoma[J].Gastroenterology, 2008, 135 (4) :1192-1199.

[6]Lok AS, McMahon BJ.Chronic hepatitis B:update 2009[J].Hepatol-ogy, 2009, 50 (3) :661-697.

[7]European Association For The Study Of The Liver.EASL Clinical Prac-tice Guidelines:management of chronic hepatitis B[J].J Hepatol, 2009, 50 (2) :227-242.

[8]Hui CK, Leung N, Yuen ST, et al.Natural history and diseaseprogression in Chinese chronic hepatitis B patients in immune-tol-erant phase[J].Hepatology, 2007, 46 (2) :395-401.

[9]Chu CM, Liaw YF.HBsAg seroclearance in asymptomatic carriers ofhigh endemic areas:appreciably high rates during a long-term follow-up[J].Hepatology, 2007, 45 (5) :1187-1192.

[10]Chen CJ, Yang HI, Iloeje UH.Hepatitis B virus DNA levels andoutcomes in chronic hepatitis B[J].Hepatology, 2009, 49 (5 Sup-pl) :S72-84.

[11]Villeneuve JP, Condreay LD, Willems B, et al.Lamivudine treat-ment for decompensated cirrhosis resulting from chronic hepatitis B[J].Hepatology, 2000, 31 (1) :207-210.

[12]Perrillo RP, Wright T, Rakela J, et al.A multicenter United States-Canadian trial to assess lamivudine monotherapy be-fore and after liver transplantation for chronic hepatitis B[J].Hepa-tology, 2001, 33 (2) :424-432.

[13]Hann HW, Fontana RJ, Wright T, et al.A United States compas-sionate use study of lamivudine treatment in nontransplantation can-didates with decompensated hepatitis B virus-related cirrhosis[J].Liver Transpl, 2003, 9 (1) :49-56.

[14]Lo CM, Liu CL, Lau GK, et al.Liver transplantation for chronichepatitis B with lamivudine-resistant YMDD mutant using add-onadefovir dipivoxil plus lamivudine[J].Liver Transpl, 2005, 11 (7) :807-813.

[15]Koda M, Nagahara T, Matono T, et al.Nucleotide analogs for pa-tients with HBV-related hepatocellular carcinoma increase the sur-vival rate through improved liver function[J].Intern Med, 2009, 48 (1) :11-17.

[16]Keeffe EB, Dieterich DT, Han SH, et al.A treatment algorithm forthe management of chronic hepatitis B virus infection in the UnitedStates:an update[J].Clin Gastroenterol Hepatol, 2006, 4 (8) :936-962.

[17]Chu CM, Liaw YF.Hepatitis B virus-related cirrhosis:naturalhistory and treatment[J].Semin Liver Dis, 2006, 26 (2) :142-152.

[18]Tai DI, Chen CH, Chang TT, et al.Eight-year nationwide surviv-al analysis in relatives of patients with hepatocellular carcinoma:role of viral infection[J].J Gastroenterol Hepatol, 2002, 17 (6) :682-689.

Relative Articles

[1]	Infectious Diseases Physicians Branch， Chinese Medical Doctor Association, Chinese Society of Infectious Diseases， Chinese Medical Association. Chinese practice guideline for the prevention and treatment of mother-to-child transmission of hepatitis B virus （version 2024）[J]. Journal of Clinical Hepatology, 2024, 40(8): 1557-1566. doi: 10.12449/JCH240809
[2]	Jianing KONG, Binbin ZHANG, Junping SHI. An excerpt of clinical practice guideline of prevention and treatment of metabolic dysfunction-associated （non-alcoholic） fatty liver disease （2024 edition）[J]. Journal of Clinical Hepatology, 2024, 40(9): 1767-1770. doi: 10.12449/JCH240908
[3]	Liver Failure and Artificial Liver Group， Chinese Society of Infectious Diseases， Chinese Medical Association, Severe Liver Disease and Artificial Liver Group， Chinese Society of Hepatology， Chinese Medical Association. Guideline for diagnosis and treatment of liver failure （2024 version）[J]. Journal of Clinical Hepatology, 2024, 40(12): 2371-2387. doi: 10.12449/JCH241206
[4]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. Journal of Clinical Hepatology, 2019, 35(1): 38-44. doi: 10.3969/j.issn.1001-5256.2019.01.007
[5]	Panel of Elastography Assessment of Liver Fibrosis, Study Group of Interventional Ultrasound, Society of Ultrasound in Medicine of Chinese Medical Association. Guidelines for clinical application of two-dimensional shear wave elastography in assessment of liver fibrosis in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(2): 255-261. doi: 10.3969/j.issn.1001-5256.2018.02.008
[6]	Dai MingJia, Leng XueJun, Yan XueBing. Interpretation of 2015 WHO guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection: comparison antiviral treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(7): 1004-1007. doi: 10.3969/j.issn.1001-5256.2015.07.003
[7]	Expert Committee for Antiviral Therapy for Special Patients with Chronic Hepatitis B;. Expert consensus on antiviral therapy for special patients with chronic hepatitis B: an update in 2015[J]. Journal of Clinical Hepatology, 2015, 31(8): 1185-1192. doi: 10.3969/j.issn.1001-5256.2015.08.002
[8]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association . The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. Journal of Clinical Hepatology, 2015, 31(12): 1941-1960. doi: 10.3969/j.issn.1001-5256.2015.12.002
[9]	Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the management of intrahepatic cholestasis of pregnancy (2015)[J]. Journal of Clinical Hepatology, 2015, 31(10): 1575-1578. doi: 10.3969/j.issn.1001-5256.2015.10.003
[10]	Chinese Society of Organ TransplantationChinese Medical Association;. Guidelines for application of tacrolimus in clinical liver transplantation[J]. Journal of Clinical Hepatology, 2015, 31(9): 1372-1374. doi: 10.3969/j.issn.1001-5256.2015.09.002
[11]	Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2015, 31(11): 1752-1769. doi: 10.3969/j.issn.1001-5256.2015.11.002
[12]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of chronic pancreatitis(2014)[J]. Journal of Clinical Hepatology, 2015, 31(3): 322-326. doi: 10.3969/j.issn.1001-5256.2015.03.002
[13]	Yan Jie, Xie Wen. Expert consenus on antiviral therapy for special patients with chronic hepatitis B: an update in 2014[J]. Journal of Clinical Hepatology, 2014, 30(7): 580-587. doi: 10.3969/j.issn.1001-5256.2014.07.002
[14]	Li XiaoQing, Qian JiaMing. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Updated June 2014[J]. Journal of Clinical Hepatology, 2014, 30(12): 1236-1239. doi: 10.3969/j.issn.1001-5256.2014.12.002
[15]	Pancreas Study Group, Chinese Society of Gastroenterology, Chinese Medical Association, Editorial Board of Chinese Journal of Pancreatology, Editorial Board of Chinese Journal of Digestion. Chinese guidelines for the management of acute pancreatitis ( Shanghai, 2013)[J]. Journal of Clinical Hepatology, 2013, 29(9): 656-660. doi: 10.3969/j.issn.1001-5256.2013.09.006
[16]	Yang Li, Lu LunGen. Introduction: EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection(2012)[J]. Journal of Clinical Hepatology, 2012, 28(6): 405-409.
[17]	Liao YunFan, Jia-Horng Kao, Teerha Piratvisuth, et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J]. Journal of Clinical Hepatology, 2012, 28(8): 641-661.
[18]	Fan Rong, Liang XieEr, Sun Jian, Hou JinLin. Explanation of the “Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update”: Treatment strategy, resistance management and non-invasive evalution of liver fibrosis[J]. Journal of Clinical Hepatology, 2012, 28(7): 484-486.
[19]	Yang Song, Cheng Jun. Interpretation of Chinese guideline on prevention and treatment for chronic hepatitis B (2011version) -status quo and prospect of antiviral therapy[J]. Journal of Clinical Hepatology, 2011, 27(8): 794-795+800.
[20]	Jia JiDong, Li LanJuan. The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J]. Journal of Clinical Hepatology, 2011, 27(1): 113-128.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3264) PDF downloads(823)

Interpretation of the guideline on prevention and treatment for chronic hepatitis B (2010 version) -the goals and indications for chronic hepatitis B treatment

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Interpretation of the guideline on prevention and treatment for chronic hepatitis B (2010 version) -the goals and indications for chronic hepatitis B treatment

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content